DOI: 10.1002/cam4.3606

ORIGINAL RESEARCH

Fatherhood status in relation to prostate cancer risks in two large **U.S.-based prospective cohort studies**

Ashley M. Geczik 💿 Scott P. Kelly	Ruth M. Pfeiffer W	Ven-Yi Huang	Linda M. Liao
Cindy K. Zhou Louise A. Brinton	Michael B. Cook		

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA

Correspondence

Michael B. Cook, Metabolic Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH, DHHS, 9609 Medical Center Drive, Room 6E430, MSC 9774, Bethesda, MD 20892-9774, USA. Email: michael.cook@nih.gov

Funding information

This work was supported by the Intramural Research Program of the National Cancer Institute.

Abstract

Background: Despite the high incidence and mortality of prostate cancer (PCa) in the Unites States, few risk factors have been consistently linked with these PCa outcomes. Assessing proxies of reproductive factors may offer insights into PCa pathogenesis. In this study, we examined fatherhood status as a proxy of fertility in relation to total, nonaggressive, aggressive, and fatal PCa.

Methods: We examined participants of two cohorts, the NIH-AARP Diet and Health (NIH-AARP) Study and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals of associations between fatherhood status and number of children sired in relation to PCa incidence.

Results: Fatherhood status (one or more children vs. childless) was positively associated with total PCa risk in NIH-AARP or PLCO, but was not statistically significant (p = 0.06 and 0.55, respectively). Number of children sired indicated a slightly elevated risk of total PCa, but HRs were rarely significant and were of a fairly constant magnitude with no discernable trend relative to the childless referent group. Associations were similar for nonaggressive and aggressive PCa. The trend test for fatal PCa was statistically significant in NIH-AARP ($p_{trend} < 0.01$), despite none of the individual categorical point estimates reaching this threshold.

Conclusion: This study provides tentative evidence that fathering children is associated with a slightly increased PCa risk. Future research should strive to assess better proxies of reproductive function in relation to aggressive and fatal PCa to provide more specific evidence for this putative relationship.

KEYWORDS

family size, fertility, offspring, prostate neoplasms, reproductive history, risk factors

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

1 | INTRODUCTION

In the United States (U.S.), the 2020 estimates for the number of new incident prostate cancer (PCa) cases is 191,930 and the estimated number of PCa-related deaths is 33,330.¹ Despite PCa being so prevalent, few factors have been consistently associated with PCa risk. Age, family history of PCa, race/ ethnicity, geographic location (including migration), and germline genetic variants are among the established risk factors.²⁻⁴ However, other risk factors that have demonstrated putative associations with PCa require further examination. In particular, sex-steroid hormones and reproductive factors have long been considered to play a role in PCa pathogenesis and progression. The number of children sired (fatherhood status) has been studied as a proxy exposure of fertility.⁵ Despite a systematic review and meta-analysis of 11 studies reporting a reduced risk of PCa associated with being childless (OR 0.91, 95% CI 0.87-0.96), there was significant between-study heterogeneity (p < 0.001, $I^2 = 88\%$).⁶ A more recent study within the UK Biobank Cohort did find a similarly reduced PCa risk associated with having never fathered children (HR 0.89, 95% CI 0.81–0.97),⁷ possibly indicating that a greater evidence base may help further elucidate this association as well as the sources of heterogeneity. This is supported by the fact that some prior studies have been limited in their ability to assess these relationships due to imprecise definitions of fatherhood status, high potentials for residual confounding, small sample sizes, and limited assessment of disease aggressiveness.

In an effort to provide more definitive findings, we examined fatherhood status as a proxy for fertility in men in relation to total, nonaggressive, aggressive, and fatal PCa risks in two large U.S.-based cohort studies; the NIH-AARP Diet and Health (NIH-AARP) Study and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. This study includes longer follow-up time than previous studies and includes stratification by tumor aggressiveness.

2 | METHODS

2.1 | Study population

2.1.1 | NIH-AARP diet and health study

This study and its participants were previously described.⁸ In brief, 567,169 individuals were enrolled from 1995 to 1996 via a baseline questionnaire (BQ), and followed up by a risk factor questionnaire (RFQ) in 1996 to 1997. The RFQ included questions about fatherhood and 334,905 of the BQ respondents returned a valid RFQ questionnaire. From these 334,905 individuals, we excluded women (n = 136,407), proxy respondents (n = 10,383), death certificate only cases of prostate cancer without a confirmed prostate cancer diagnosis (n = 1580), men

diagnosed with any cancer (excluding nonmelanoma skin cancer) prior to the return of their RFQ questionnaire (n = 9634), men diagnosed with carcinoma in situ or stage 0 PCa (n = 62), men with diagnosis dates equal to the date of RFQ questionnaire return (10), and men with incomplete fatherhood responses (missing number of sons and/or number of daughters, n = 14,904), resulting in 161,925 men in our analytic population. In a sensitivity analysis, we added back into the analytic population men who had partially incomplete fatherhood responses (missing number of sons or missing number of daughters, with the missing response recoded to "0" providing for a total sensitivity analytic population of 162,894 [Table S1]).

For the RFQ questionnaire the following questions were asked in reference to number of children sired: "Do you have any full- or half-sisters, full- or half-brothers, daughters, or sons, either living or deceased? Include blood relatives only (if no, skip ahead)," "How many daughters do you have, both living and deceased? Include blood relatives only," and "How many sons do you have, both living and deceased? Include blood relatives only."

2.1.2 | PLCO cancer screening trial

This study and its participants were previously described.⁹ In brief, 154,887 individuals were enrolled from 1993 to 2001. A baseline questionnaire (BQ) was completed at enrollment and a supplemental questionnaire (SQX) that included questions on fatherhood was sent to all participants during 2006-2008. 102,884 of the BQ respondents returned a valid SQX questionnaire. From these 102,884 individuals, we excluded women (n = 54,679), men with any cancer diagnosis (excluding nonmelanoma skin cancer) prior to the return of their SQX questionnaire (n = 8105), and incomplete fatherhood responses (n = 13,252), resulting in 26,848 men in our analytic population. The sensitivity analysis with recoded partially incomplete fatherhood responses (as done for NIH-AARP) added back 3519 men to the PLCO cohort, providing for a total sensitivity analytic population of 30,367 (Table S1).

For the SQX questionnaire, there were check boxes for respondents to record numbers of isisters, brothers, daughters, and sons. The question that headed these response check boxes were as follows: "How many of each of the following blood relatives (do not count half-sisters or half-brothers) do/ did you have? (Please include any deceased)."

2.2 | Identification of incident PCa cases and PCa-specific mortality

The primary outcome of interest for our analyses was first incident PCa, as well as the subsets of nonaggressive and aggressive PCa. We defined nonaggressive and aggressive PCa using the clinical cancer stage and Gleason score information from both the NIH-AARP and PLCO cohorts. Clinical cancer stage was determined using the TNM staging system and categorized according to the American Joint Committee on Cancer (AJCC) Staging Manual, fifth edition. For our analysis, nonaggressive PCa was defined as clinical cancer stage \leq II or Gleason score <8, and aggressive PCa was defined as clinical cancer stage \leq III, Gleason score \geq 8 and/or fatal PCa for NIH-AARP and PLCO. The nonaggressive and aggressive PCa cases do not sum to total PCa, since some individuals with confirmed PCa did not report data on stage or grade.

Our secondary outcome of interest was fatal PCa, which was defined as PCa being the underlying cause of death with a prior confirmed PCa diagnosis. Fatal PCa cases were ascertained through periodic linkage to the National Death Index (NDI), cancer registry linkage, and Social Security Administration Death Master File, with confirmation from proxy responses.⁸ Due to limited fatal PCa cases in the PLCO cohort (n = 3 childless men, n = 69 fathers), we were only able to examine this outcome in the NIH-AARP cohort.

2.3 | Statistical analyses

Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between fatherhood status and PCa incidence and mortality. Tests for trend were conducted by treating the number of offspring as a continuous variable in the Cox regression model. For our analyses of incident PCa risks, follow-up time started at calendar month (from which offspring status was recalled) and continued until event of interest (incident PCa) or right censoring due to loss to follow-up, death, incidence of other cancer diagnosis, or end of follow-up (NIH-AARP: 31 December 2011; PLCO: 31 December 2014), whichever occurred first. For our analysis of fatal PCa, follow-up time started at calendar month (from which offspring status was recalled) and continued until event of interest (PCa-specific mortality) or right censoring due to loss to follow-up, death due to another cause, or end of follow-up up (NIH-AARP: 31 December 2011; PLCO: 31 December 2014). Calendar time was used as the underlying time metric and the baseline hazards were stratified by categorical age groups (NIH-AARP: ≤55, 55-60, 60-65, 65-70, and >70 years old; PLCO: $\leq 65, 65-70, 70-75, 75-80$, and >80 years old). We assessed the proportional hazards assumption by testing whether smoothed, scaled Schoenfeld residuals significantly deviated from a nonzero slope when regressed against log time.

Covariates that were, a priori, deemed to be potential confounders included: education, race, marital status, state/ center, and randomization arm (PLCO). All statistical tests were two-sided and statistical significance was defined as p < 0.05.

To assess potential effect measure modification of marital status and PSA screening history, we compared nested models with the inclusion of multiplicative interaction terms and tested whether model fit was significantly improved using the likelihood ratio test. Stratified analyses were conducted if statistically significant (p < 0.05) effect measure modification was detected.

Sensitivity analyses included: (a) recoding partially incomplete fatherhood responses (daughter or son) to zero; (b) reclassifying marital status from three categories (never married, formerly married/widowed, and currently married) to four (never married, married, formerly married, and widowed); and, (c) excluding never married men.⁸ Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc.).

3 | RESULTS

Descriptive statistics for each of the two cohorts are shown in Table 1. At the time that fatherhood status was ascertained, men in the NIH-AARP cohort had a younger average age $(63 \pm 5 \text{ years})$ compared with men in PLCO $(71 \pm 6 \text{ years})$. Men enrolled in NIH-AARP were more likely to have obtained a college or higher degree (70%) compared with men enrolled in PLCO (46%). Higher proportions of NIH-AARP (72% prostate-specific antigen [PSA], 84% digital rectal examination [DRE]) participants had undergone prostate cancer screening compared with PLCO trial (47% PSA, 57% DRE) participants. Annual household income, provided via census collected data for NIH-AARP participants, showed that NIH-AARP and PLCO had a similar distribution with a majority of men falling in the \$20,000-\$49,999 income bracket followed by the \$50,000-\$99,999 income bracket. Most men reported no family history of prostate cancer in both NIH-AARP (86%) and PLCO (91%). Other descriptive characteristics were similar across both cohorts.

The median person-years of follow-up for NIH-AARP was 15.1 and for PLCO was 7.9. There were 17,841 incident PCas in NIH-AARP and 1779 incident PCas in PLCO. Of these, 4512 (25%) and 377 (21%) were aggressive in NIH-AARP and PLCO, respectively (Table 1). There were 710 fatal PCas in NIH-AARP and 72 in PLCO (Table 1). When we included individuals that had partially incomplete fatherhood responses, there were very small increases in these numbers (total incident PCas = 17,941 in NIH-AARP and 1987 in PLCO; Table S1).

For NIH-AARP, the association of fatherhood status (one or more child vs. childless) with total PCa was positive (HR=1.06), but did not reach the designated threshold

-WILEY

TABLE 1 Descriptive characteristics of men by cohort according to prostate cancer status

	NIH-AAI	RP								
	Total pop	oulation	Prostate	cancer cases	Nonaggr prostate		Aggress cancer	sive prostate	Fatal cance	prostate r
Descriptive characteristics	N	%	N	%	N	%	N	%	N	%
Number of participants	161,925		17,841		13,041		4512		710	
Enty age (mean, SD)	63.0 ± 5.3	3	63.6 ± 5.0)	$63.6 \pm 5.$	0	63.6 ± 5	5.0	65.2 <u>+</u>	- 4.4
BMI (mean, SD)	27.1 ± 4.2	2	26.8 ± 3.8	3	$27.0 \pm 3.$	8	27.0 ± 4	1.0	27.2 ±	<u>-</u> 4.0
Height (mean, SD)	70.2 ± 2.9)	70.2 ± 2.9)	$70.2 \pm 2.$	9	70.3 ± 2	2.9	70.5 <u>+</u>	2.9
Fatherhood status										
Childless	17,986	11.1	1794	10.1	1315	10.1	449	10.0	77	10.8
One or more children	143,939	88.9	16,047	89.9	11,726	89.9	4063	90.0	633	89.2
Marital status										
Currently married/living as married	138,431	85.5	15,548	87.1	11,404	87.4	138	3.1	27	3.8
Formerly married/ widowed	17,059	10.5	1682	9.4	1197	9.2	453	10.0	93	13.1
Never married	5613	3.5	536	3.0	386	3.0	3903	86.5	586	82.5
Unknown	822	0.5	75	0.4	54	0.4	18	0.4	4	0.6
Education										
<12 years	7399	4.6	726	4.1	521	4.0	179	4.0	31	4.4
High school/some college	38,051	23.5	3930	22.0	2868	22.0	1012	22.4	172	24.2
College degree or higher	112,898	69.7	12,806	71.8	9370	71.9	3231	71.6	489	68.9
Unknown	3577	2.2	379	2.1	282	2.2	90	2.0	18	2.5
Race										
White	151,812	93.8	16,580	92.9	12,114	92.9	4193	92.9	662	93.2
Black	3514	2.2	621	3.5	459	3.5	156	3.5	29	4.1
Other	4982	3.1	470	2.6	335	2.6	128	2.8	10	1.4
Unknown	1617	1.0	170	1.0	133	1.0	35	0.8	9	1.3
Income										
<\$20,000	1620	1.0	166	0.9	113	0.9	50	1.1	10	1.4
\$20,000-\$49,999	77,394	47.8	8234	46.2	6033	46.3	2051	45.5	343	48.3
\$50,000-\$99,999	73,394	45.3	8269	46.3	6044	46.3	2105	46.7	321	45.2
\$100,000-\$200,000	9419	5.8	1162	6.5	842	6.5	306	6.8	36	5.1
>\$200,000	98	0.1	10	0.1	9	0.1	0	0.0	0	0.0
Prefer not to answer										
Unknown										
Smoking status										
Never	48,140	29.7	5994	33.6	4418	33.9	1484	32.9	176	24.8
Former	93,296	57.6	9957	55.8	7299	56.0	2499	55.4	412	58.0
Current	14,997	9.3	1309	7.3	914	7.0	373	8.3	94	13.2
Unknown	5492	3.4	581	3.3	410	3.1	156	3.5	28	3.9
Family first degree history o	f prostate ca	uncer								
No	139,468	86.1	14,997	84.1	10,930	83.8	3817	84.6	575	81.0
Yes	4980	3.1	949	5.3	707	5.4	226	5.0	45	6.3
Unknown	17,477	10.8	1895	10.6	1404	10.8	469	10.4	90	12.7

GECZIK ET AL.

409	

-WILEY

Total pop	ulation	Prostate o	cancer cases	Nonaggre cancer	ssive prostate	Aggress cancer	ive prostate	Fatal p cancer	rostate
N	%	N	%	N	%	N	%	N	%
26,848		1779		1399		377		72	
71.2 ± 5.8		70.6 ± 5.4		70.1 ± 5.2		72.5 ± 5	.7	75.0 ±	6.1
27.7 ± 4.4		27.5 ± 4.1		27.5 ± 4.0		27.5 ± 4	.4	27.0 ±	4.0
69.8 ± 2.8		69.8 ± 2.8		69.9 ± 2.8		69.5 ± 2		69.0 ±	
1922	7.2	123	6.9	102	7.3	21	5.6	3	4.2
24,926	92.8	1656	93.1	1297	92.7	356	94.4	69	95.8
22,441	83.6	1526	85.8	1211	86.6	312	82.8	54	75.0
3735	13.9	207	11.6	148	10.6	59	15.6	17	23.6
485	1.8	31	1.7	27	1.9	4	1.1	1	1.4
187	0.7	15	0.8	13	0.9	2	0.5	0	0.0
1440	5.4	71	4.0	54	3.9	17	4.5	4	5.6
12,939	48.2	838	47.1	646	46.2	191	50.7	39	54.2
12,414	46.2	865	48.6	695	49.7	168	44.6	29	40.3
55	0.2	5	0.3	4	0.3	1	0.3	0	0.0
24,307	90.5	1584	89.0	1250	89.3	331	87.8	61	84.7
516	1.9	53	3.0	36	2.6	17	4.5	3	4.2
1494	5.6	108	6.1	84	6.0	24	6.4	6	8.3
531	2.0	34	1.9	29	2.1	5	1.3	2	2.8
				_,					
1913	7.1	103	5.8	76	5.4	26	6.9	9	12.5
9817	36.6	600	33.7	448	32.0	152	40.3	31	43.1
8429	31.4	594	33.4	501	35.8	92	24.4	14	19.4
2627	9.8	226	12.7	187	13.4	39	10.3	4	5.6
480	1.8	42	2.4	33	2.4	9	2.4	1	1.4
2595	9.7	144	8.1	97	6.9	46	12.2	10	13.9
987	3.7	70	3.9	57	4.1	13	3.4	3	4.2
07(0	26.4	607	20.2	~~~	20.7		07.4	07	07.5
9768	36.4	697	39.2	555	39.7	141	37.4	27	37.5
15,037	56.0	969	54.5	746	53.3	211	56.0	40	55.6
1776	6.6	106	6.0	87	6.2	19	5.0	4	5.6
267	1.0	17	1.0	11	0.8	6	1.6	1	1.4
2 4 26 4	00 -	1 == 0	00.2	1000	00.1	225	00.0		o
24,304	90.5	1570	88.3	1232	88.1	335	88.9	66	91.7
	7.2	187	10.5	151	10.8	36	9.5	6	8.3
601	2.2	22	1.2	16	1.1	6	1.6	0	0.0

(Continues)

TABLE 1 (Continued)

	NIH-AAI	RP								
	Total pop	oulation	Prostate	cancer cases	Nonaggr prostate		Aggress cancer	ive prostate	Fatal j cancer	prostate r
Descriptive characteristics	Ν	%	Ν	%	Ν	%	N	%	N	%
PSA screening history										
No	33,290	20.6	3098	17.4	2100	16.1	942	20.9	197	27.7
Yes	116,118	71.7	13,568	76.0	10,116	77.6	3231	71.6	455	64.1
Unknown	12,517	7.7	1175	6.6	825	6.3	339	7.5	58	8.2
Digital rectal examination h	nistory									
No	22,273	13.8	2090	11.7	1411	10.8	639	14.2	139	19.6
Yes	135,619	83.8	15,351	86.0	11,348	87.0	3763	83.4	555	78.2
Unknown	4033	2.5	400	2.2	282	2.2	110	2.4	16	2.3
Diabetes										
No	146,449	90.4	16,697	93.6	12,221	93.7	4209	93.3	660	93.0
Yes	15,476	9.6	1144	6.4	820	6.3	303	6.7	50	7.0
Unknown	N/A ^a	N/A ^a	N/A ^a	N/A ^a	N/A ^a	N/A ^a				

Abbreviations: BMI, body mass index; PSA, prostate specific antigen.

^aNot applicable because the question only elicited affirmative responses for this condition and was therefore coded binary.

for statistical significance (p = 0.06). Associations between fatherhood status and nonaggressive, aggressive, and fatal PCa risks were in a similar direction, but with larger p values (Table 2). For PLCO, associations were also positive, but not statistically significant for total, nonaggressive, and aggressive PCa risk. The 72 fatal PCa cases in PLCO were not amenable to a converged model likely due to the fact that only three men had indicated they were childless. Associations were similar when including the small additional number of men with partially incomplete fatherhood questionnaire responses (Table S2).

Assessment of the association between number of children sired and PCa risk were similar across the two cohorts (Table 3), with slightly elevated HRs that were rarely significant and were of a fairly constant magnitude with no discernable trend relative to the childless referent group. This was true for total, nonaggressive, and aggressive PCa, with the latter showing a slightly stronger, albeit nonsignificant, association in PLCO compared with NIH-AARP. The trend test for fatal PCa was statistically significant in NIH-AARP $(p_{\text{trend}} = 0.0047)$, despite none of the individual categorical point estimates reaching this threshold.

There was no evidence of effect measure modification by marital status (total PCa, p = 0.23 for NIH-AARP and p = 0.49 for PLCO; nonaggressive PCa, p = 0.10 for NIH-AARP and p = 0.51 for PLCO; aggressive PCa, p = 0.71for NIH-AARP and p = 0.88 for PLCO; and fatal PCa, p = 0.84 for NIH-AARP). There was tentative evidence for effect measure modification by PSA screening history

in NIH-AARP (total PCa, p = 0.05 for NIH-AARP and p = 0.06 for PLCO; nonaggressive PCA, p = 0.37 for NIH-AARP and p = 0.06 for PLCO; aggressive PCa, p = 0.04for NIH-AARP and p = 0.75 for PLCO; and fatal PCa, p = 0.99 for NIH-AARP) and stratified analyses by PSA screening history for NIH-AARP examining total PCa and aggressive PCa risk (Table S4). Sensitivity analyses of reclassification of marital status and exclusion of never married men did not materially change the presented results (results not shown). Associations for both NIH-AARP and PLCO cohorts were unaltered when we included subjects with partially incomplete fatherhood responses (Tables S1-S3).

DISCUSSION 4

In this study of two large U.S.-based prospective cohort studies with long follow-up, we examined the association between fatherhood status and PCa risks. Fatherhood status (one or more children vs. childless) was positively associated with total PCa risk in NIH-AARP or PLCO, but was not statistically significant. We observed slightly elevated risk of total, nonaggressive, and aggressive PCa risk in relation to number of children sired, but HRs were rarely significant and were of a fairly constant magnitude with no discernable trend relative to the childless referent group. The trend test for fatal PCa, in NIH-AARP, was statistically significant even though none of the individual categorical point estimates reached DI CO

	-	-
_		

WILEY

				Nonogano	acivo prostato	Aggroog	ivo prostato	Fotol n	mostata
Total pop	ulation	Prostate	cancer cases	cancer	ssive prostate	Aggressive prostate cancer		cancer	prostate
Ν	%	Ν	%	Ν	%	N	% N		%
12,034	44.8	801	45.0	626	44.7	174	46.2	37	51.4
12,604	46.9	832	46.8	663	47.4	167	44.3	29	40.3
2210	8.2	146	8.2	110	7.9	36	9.5	6	8.3
10,753	40.1	726	40.8	571	40.8	154	40.8	30	41.7
15,418	57.4	1013	56.9	798	57.0	213	56.5	41	56.9
677	2.5	40	2.2	30	2.1	10	2.7	1	1.4
21,831	81.3	1479	83.1	1177	84.1	300	79.6	55	76.4
4237	15.8	246	13.8	180	12.9	65	17.2	15	20.8
780	2.9	54	3.0	42	3.0	12	3.2	2	2.8

this threshold. Overall, this study provides tentative evidence that fathering children is associated with a slightly increased PCa risk.

A prior meta-analysis of 11 studies has also reported a significant reduction in PCa risk for childless men compared with men who had fathered at least one child (OR 0.91, 95% CI 0.87-0.96), but there was significant between-study heterogeneity,⁶ underscoring the inconsistency in the existing literature. Previous studies have observed a reduced risk of PCa among childless men compared to men that are fathers.^{6,7} Potential explanations for inconsistent results include the inability to discern intention versus infertility, as well as geographical, financial, and birth cohort differences that could affect the magnitude of such bias. Given the complex wording of questions and responder-determined skip patterns in extensive questionnaires, exposure ascertainment bias may also contribute to between-study heterogeneity. Despite these inconsistencies, there is lateral supporting evidence that men whose female partners used in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) had an increased risk of PCa, particularly earlier disease, compared with men who succeeded in natural conception.¹⁰

Biological explanations that may underlie the observed association between subfertility and PCa may be PSA dynamics,¹¹ local (prostate) inflammation,¹² Y chromosome genetics/epigenetics,¹³ shared genetic etiology such as DNA repair,¹⁴ environmental exposures such as endocrine disrupting chemicals,¹⁵ among other hypotheses.^{16,17}

Strengths of our study include the similarity of the questionnaires and descriptive characteristics of NIH-AARP and PLCO for comparison, the large sample sizes available for analysis, and the availability of a range of covariates that we assessed as potential confounders and effect modifiers. Another strength of our study is the use of extended follow-up data on case ascertainment and mortality for the men in NIH-AARP from the prior analysis using this cohort (17,841 PCa cases in our analysis vs. 8134 PCa cases⁸ in a prior analysis). A limitation of our study was the small number of childless prostate cancer cases in the PLCO cohort. As such, we recommend a cautious interpretation of the PLCO results and a greater reliance being placed on estimates from NIH-AARP. The use of childless status as a proxy for subfertility is a limitation and we did not have information to assess to what degree this population represented subfertility/infertility or was attributable to personal preference. Additionally, the high number of men that did not provide responses on number of offspring is a limitation for this study. In examining the questionnaires from NIH-AARP and PLCO, it is possible that the men accidentally skipped over these questions if they did not have siblings without realizing the questions were relevant to siblings and offspring. A final limitation is that we were unable to examine fatal PCa in the PLCO cohort due to a limited number of outcomes (n = 72).

Future research should strive to assess more specific metrics of reproductive function—such as subfertility/in-fertility, primary/secondary hypogonadism, and hormone

TABLE 2 Adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for each cohort according to prostate cancer status with baseline hazards stratified by age group

	NIH-AARP ^a	RP ^a										
	Total cas	Total cases $(n = 17, 841)$		Nonaggre	Nonaggressive cases $(n = 13,041)$	041)	Aggressi	Aggressive cases $(n = 4512)$		Fatal cas	Fatal cases $(n = 710)$	
	Cases	HR (95% CI)	<i>p</i> value	Cases	HR (95% CI)	<i>p</i> value	Cases	HR (95% CI)	<i>p</i> value	Cases	HR (95% CI)	<i>p</i> value
Fatherhood status												
Childless	1794	Reference		1315	Reference		449	Reference		77	Reference	
1 or more children	16,047	1.06 (1.00, 1.12)	0.06	11,726	1.04 (0.98–1.11)	0.22	4063	1.09 (0.97–1.22)	0.13	633	1.04 (0.78–1.39)	0.78
	PLC0 ^b											
	Total ca	Total cases $(n = 1779)$		Nonaggr	Nonaggressive cases $(n = 1399)$	(66)	Aggres	Aggressive cases $(n = 377)$		Fatal c	Fatal cases $(n = 72)^{c}$	
	Cases	HR (95% CI)	p value	Cases	HR (95% CI)	p value	Cases	HR (95% CI)	p value	Cases	HR (95% CI)	<i>p</i> value
Fatherhood status												
Childless	123	Reference		102	Reference		21	Reference		ю	Reference	
1 or more children	1656	1.07 (0.87–1.32)	0.55	1297	1.03 (0.81–1.29)	0.83	356	1.24 (0.76–2.01)	0.39	69		
^a Adjusted for: education currently married, unk	on status (<1 nown), and s	^a Adjusted for: education status (<12 years, HS/some college, college graduate or higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, currently married, unknown), and state of residence at baseline (California, Florida, Georgia, Louisiana, Michigan, North Carolina, New Jersey, Pennsylvania).	e, college gradt ine (California,	ate or higher, , Florida, Geo	unknown), race (White rgia, Louisiana, Michige	e/non-Hispanic, an, North Carol	Black/non-F ina, New Jer	fispanic, other, unknown sey, Pennsylvania).	ı), marital statı	ıs (never mar	ried, formerly married/	vidowed,
^b Adjusted for: educati currently married, unk	on status (<1 nown), rando	^b Adjusted for: education status (<12 years, HS/some college, college graduate or higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, currently married, unknown), randomization arm (intervention, control), and center of enrollment (University of Colorado, Georgetown University, Pacific Health Research and Education Institute (Honolulu), Henry Ford Health	e, college gradt on, control), an	uate or higher, id center of er	, unknown), race (White nollment (University of	2/non-Hispanic, Colorado, Geo	Black/non-F	higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, cer of enrollment (University of Colorado, Georgetown University, Pacific Health Research and Education Institute (Honolulu). Henry Ford Hea	1), marital statu tesearch and E	as (never mar ducation Inst	ried, formerly married/ itute (Honolulu), Henry	widowed, Ford Health

ord Health System, University of Minnesota, Washington University in St. Louis, University of Pittsburgh, University of Utah, Marshfield Clinic Research Foundation, University of Alabama at Birmingham). °PLCO prostate cancer specific mortality was not able to be examined for survival analysis to estimate hazard ratios due to limited number of childless men having prostate cancer. currenuy

412 WILEY-Cancer Medicine

Total (n = 17,841) No Zases HR (95% CI) p value Ca Fatherhood status 1794 Reference - 1 Childless 1794 Reference - 1 I or more children 16,047 1.06 (1.00, 1.12) 0.06 11, 2 or more children 14,392 1.07 (1.01, 1.13) 0.02 6 3 or more children 8915 1.07 (1.01, 1.13) 0.02 6 3 or more children 4232 1.06 (0.99, 1.13) 0.08 3 4 or more children 1744 1.05 (0.98, 1.13) 0.16 1 1 1 1.01 (1.00-1.02) 0.18 No Trend 1 1.01 (1.00-1.02) 0.18 No Farend 1 1.01 (1.00-1.02) 0.18 No Trend 1 1.01 (1.00-1.02) 0.18 No Farence 1 1.01 (1.00-1.02) 0.18 No Farence 1 1.01 (1.00-1.02) 0.18	Nonaggressive (n : Cases HR (95 Cases HR (05 1315 Referen 11,726 1.04 (0 10,535 1.05 (0 6509 1.05 (0 3075 1.04 (0 1276 1.04 (0 1276 1.04 (0 1276 1.04 (0 1276 1.04 (0	Nonaggressive (n = 13,041) Cases HR (95% CI) 1315 Reference 11,726 1.04 (0.98, 1.11) 10,535 1.05 (0.98, 1.12) 6509 1.05 (0.98, 1.12) 3075 1.04 (0.96, 1.12) 1276 1.04 (0.96, 1.13) 1276 1.04 (0.96, 1.12) 1276 1.04 (0.96, 1.12)	Ine -	Aggressiv Cases	Aggressive $(n = 4512)$				
Cases HR (95% CI) p value hood status 1794 Reference $-$ more children 16,047 1.06 (1.00, 1.12) 0.06 more children 14,392 1.07 (1.01, 1.13) 0.02 more children 8915 1.07 (1.01, 1.13) 0.02 more children 8915 1.07 (1.01, 1.13) 0.02 more children 1744 1.05 (0.99, 1.13) 0.08 more children 1744 1.01 (1.00-1.02) 0.18 more children 1.01 (1.00-1.02) 0.18 0.16 more children 1.01 (1.00-1.02) 0.18 0.16 more children 1.01 (1.00-1.02) 0.18 0.16 hood status 1.01 (1.00-1.02) 0.18 0.16 fidless 123 Reference $ -$ thood status 123 Reference $ -$ thood status 123 Reference $ -$ thood status 123 Reference $ -$	Cases 1315 11,726 10,535 6509 3075 1276 1276	HR (95% CI) Reference 1.04 (0.98, 1.11) 1.05 (0.98, 1.12) 1.05 (0.98, 1.13) 1.04 (0.96, 1.13) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)		Cases			Fatal (n :	= 710)	
hood status 1794 Reference $-$ more children 16,047 1.06 (1.00, 1.12) 0.06 more children 14,392 1.06 (1.00, 1.12) 0.05 more children 14,392 1.07 (1.01, 1.13) 0.05 more children 8915 1.07 (1.01, 1.13) 0.06 more children 4232 1.06 (0.99, 1.13) 0.08 more children 1744 1.05 (0.98, 1.13) 0.16 more children 1741 1.05 (0.98, 1.13) 0.16 more children 1744 1.05 (0.98, 1.13) 0.16 more children 1744 1.05 (0.98, 1.13) 0.16 hood status 1.01 (1.00-1.02) 0.18 1.01 fdless 1.01 (0.01.02) 0.18 1.01 fdless 123 Reference - fdless 123 Reference - fnood status 1.07 (0.87, 1.32) 0.56 fnore children 1.07 (0.87, 1.33) 0.50	1315 11,726 10,535 6509 3075 1276 1276	Reference 1.04 (0.98, 1.11) 1.05 (0.98, 1.12) 1.05 (0.98, 1.13) 1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)	— 0.22 0.18		HR (95% CI)	p value	Cases	HR (95% CI)	<i>p</i> value
	1315 11,726 10,535 6509 3075 1276 1276	Reference 1.04 (0.98, 1.11) 1.05 (0.98, 1.12) 1.05 (0.98, 1.13) 1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)	0.22 0.18						
more children 16,047 1.06 (1.00, 1.12) 0.06 more children 14,392 1.06 (1.00, 1.12) 0.05 more children 8915 1.07 (1.01, 1.13) 0.05 more children 8915 1.07 (1.01, 1.13) 0.02 more children 4232 1.06 (0.99, 1.13) 0.08 more children 1744 1.05 (0.98, 1.13) 0.16 more children 1741 1.05 (0.98, 1.13) 0.16 PLCO ^b 1.01 (1.00-1.02) 0.18 0.16 PLCO ^b 1.01 (1.00-1.02) 0.18 0.16 fild it 1.01 (1.00-1.02) 0.18 0.16 fild ot attax 1.01 (1.00-1.02) 0.18 0.16 fild sc HR (95% CI) p value 0.16 fildes 123 Reference - fidless 123 Reference - fidless 1.07 (0.87, 1.32) 0.56 finore children 1.07 (0.87, 1.32) 0.54	11,726 10,535 6509 3075 1276 1276	1.04 (0.98, 1.11) 1.05 (0.98, 1.12) 1.05 (0.98, 1.13) 1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)	0.22 0.18	449	Reference		LL	Reference	
more children 14,392 1.06 (1.00, 1.12) 0.05 1 more children 8915 $1.07 (1.01, 1.13)$ 0.02 more children 4232 $1.07 (1.01, 1.13)$ 0.02 more children 4232 $1.06 (0.99, 1.13)$ 0.02 more children 1744 $1.05 (0.98, 1.13)$ 0.16 more children 1744 $1.00 (1.00-1.02)$ 0.18 PLCO ^b $1.01 (1.00-1.02)$ 0.18 PLCO ^b $1.01 (1.00-1.02)$ 0.18 hood status $1.01 (1.00-1.02)$ 0.18 hood status $1.01 (1.00-1.02)$ 0.18 thood status $1.01 (1.00-1.02)$ 0.18 thood status $1.01 (0.87, 1.32)$ 0.55 thoore children 1.567 $1.07 (0.87, 1.32)$ 0.50 thoore children $1.07 (0.87, 1.32)$ 0.54	10,535 6509 3075 1276 Nonaggree	1.05 (0.98, 1.12) 1.05 (0.98, 1.13) 1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)	0.18	4063	1.09 (0.97, 1.22)	0.13	633	1.04 (0.78, 1.39)	0.78
more children 8915 $1.07 (1.01, 1.13)$ 0.02 more children 4232 $1.06 (0.99, 1.13)$ 0.08 more children 1744 $1.05 (0.98, 1.13)$ 0.16 more children 1744 $1.05 (0.98, 1.13)$ 0.16 more children 1744 $1.05 (0.98, 1.13)$ 0.16 PLCO ^b $1.01 (1.00-1.02)$ 0.18 PLCO ^b $Total (n = 1779)$ $p.18$ hood status $Total (n = 1779)$ $p.value$ thood status 123 Reference $-$ thood status 123 $Reference$ $-$ thore children 1656 $1.07 (0.87, 1.32)$ 0.55 thore children 1567 $1.07 (0.87, 1.33)$ 0.50	6509 3075 1276 Nonaggree	1.05 (0.98, 1.13) 1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)		3634	1.09 (0.97, 1.22)	0.14	572	1.05 (0.79, 1.40)	0.74
	3075 1276 Nonagree	1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.00 (0.99–1.02)	0.13	2256	1.11 (0.98, 1.24)	0.09	381	1.11 (0.83, 1.48)	0.50
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	1276 Nonagree	1.04 (0.96, 1.13) 1.00 (0.99–1.02)	0.33	1086	1.11 (0.98, 1.26)	0.10	209	1.24 (0.91, 1.68)	0.17
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Nonaggree	1.00 (0.99–1.02)	0.37	440	1.09 (0.94, 1.26)	0.26	92	1.29 (0.92, 1.83)	0.14
PLCO ^b Total $(n = 1779)$ Zases HR (95% CI) p value 123 Reference 123 Reference ren 1656 1.07 (0.87, 1.32) 0.55 ren 1080 1.07 (0.86, 1.32) 0.50	Nonaggree		0.47		1.01 (0.99-1.03)	0.20		1.07 (1.02–1.12)	<0.01
Total $(n = 1779)$ Total $(n = 1779)$ Cases HR (95% CI) p value 123 Reference $-$ ren 1656 1.07 (0.87, 1.32) 0.55 ren 1567 1.07 (0.86, 1.32) 0.56 ren 1080 1.07 (0.86, 1.32) 0.50	Nonaggree								
Cases HR (95% CI) p value 123 Reference - ren 1656 1.07 (0.87, 1.32) 0.55 ren 1567 1.07 (0.87, 1.33) 0.50 ren 1080 1.07 (0.86, 1.32) 0.54		ssive $(n = 1399)$		Aggress	Aggressive $(n = 377)$		Fatal (n	$n = 72)^{c}$	
123 Reference – ren 1656 1.07 (0.87, 1.32) 0.55 1 ren 1567 1.07 (0.87, 1.33) 0.50 1 ren 1080 1.07 (0.86, 1.32) 0.54	Cases	HR (95% CI)	<i>p</i> value	Cases	HR (95% CI)	<i>p</i> value	Cases	HR (95% CI)	p value
123 Reference 1656 1.07 (0.87, 1.32) 0.55 1 1567 1.07 (0.87, 1.33) 0.50 1 1080 1.07 (0.86, 1.32) 0.54									
1656 1.07 (0.87, 1.32) 0.55 1 1567 1.07 (0.87, 1.33) 0.50 1 1080 1.07 (0.86, 1.32) 0.54	102	Reference		21	Reference		ю	Reference	
1567 1.07 (0.87, 1.33) 0.50 1 1080 1.07 (0.86, 1.32) 0.54	1297	1.03 (0.81, 1.29)	0.83	356	1.24 (0.76, 2.01)	0.39	69		
1080 1.07 (0.86, 1.32) 0.54	1221	1.03 (0.81, 1.30)	0.82	343	1.27 (0.78, 2.07)	0.34	68		
	832	1.02 (0.81, 1.30)	0.86	246	1.27 (0.77, 2.07)	0.35	53		
4 or more children 609 1.11 (0.89, 1.38) 0.37 4	470	$1.08\ (0.84,1.38)$	0.55	137	1.22 (0.73, 2.02)	0.44	33		
5 or more children 298 1.12 (0.89, 1.42) 0.33 2	230	1.11 (0.85, 1.45)	0.44	67	1.20 (0.70, 2.05)	0.51	13		
Trend 1.01 (0.98–1.04) 0.49		1.01 (0.98–1.04)	0.62		1.02 (0.95–1.08)	0.62			
^a Adjusted for: education status (<12 years, HS/some college, college graduate or higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, currently married, unknown), and state of residence at baseline (California, Florida, Georgia, Louisiana, Nichigan, North Carolina, New Jersey, Pennsylvania). ^b Adjusted for: education status (<12 years, HS/some college, college graduate or higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, currently married, unknown), randomization arm (intervention, control), and center of enrollment (University of Colorado, Georgetown University, Pacific Health Research and Education Institute (Honolulu), Henry Ford Health System, University of Minnesota, Washington University in St. Louis, University of Vitah, Marshfield Clinic Research Foundation, University of Alabama at Birmingham).	or higher, unkn rida, Georgia, I or higher, unkn enter of enrollm ity of Pittsburg	higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, la, Georgia, Louisiana, Michigan, North Carolina, New Jersey, Pennsylvania). higher, unknown), race (White/non-Hispanic, Black/non-Hispanic, other, unknown), marital status (never married, formerly married/widowed, er of enrollment (University of Colorado, Georgetown University, Pacific Health Research and Education Institute (Honolulu), Henry Ford Her of Pittsburgh, University of Utah, Marshfield Clinic Research Foundation, University of Alabama at Birmingham).	Hispanic, Bla rth Carolina, Hispanic, Bla rado, Georgei farshfield Cli	ck/non-His New Jerse ck/non-His town Unive nic Researc	panic, other, unknown) y, Pennsylvania). panic, other, unknown) rsity, Pacific Health Re h Foundation, Universi	, marital statu , marital statu seearch and Edity of Alabam	s (never mar s (never mar lucation Inst a at Birming)	ried, formerly married/ ried, formerly married/ itute (Honolulu), Henry ham).	vidowed, vidowed, Ford Health

GECZIK ET AL.

WILEY

therapies—in relation to aggressive and fatal PCa to provide stronger evidence and further insight into these putative relationships.

ACKNOWLEDGMENTS

Thank you to NIH-AARP coordinator, Linda M. Liao, for data support and management. Thank you to Information Management Services, Inc. staff (Rusty Shields, Jerome Mabie, Dave S. Campbell, Patrick Wright, Thomas Riley, Tom Hickey, and Emily Carver) for technical and logistical support.

The NIH-AARP Diet and Health study was supported by the Intramural Research Program of the NIH, National Cancer Institute. Cancer incidence data from the Atlanta metropolitan area were collected by the Georgia Center for Cancer Statistics, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. Cancer incidence data from California were collected by the California Cancer Registry, California Department of Public Health's Cancer Surveillance and Research Branch, Sacramento, California. Cancer incidence data from the Detroit metropolitan area were collected by the Michigan Cancer Surveillance Program, Community Health Administration, Lansing, Michigan. The Florida cancer incidence data used in this report were collected by the Florida Cancer Data System (Miami, Florida) under contract with the Florida Department of Health, Tallahassee, Florida. The views expressed herein are solely those of the authors and do not necessarily reflect those of the FCDC or FDOH. Cancer incidence data from Louisiana were collected by the Louisiana Tumor Registry, Louisiana State University Health Sciences Center School of Public Health, New Orleans, Louisiana. Cancer incidence data from New Jersey were collected by the New Jersey State Cancer Registry, The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. Cancer incidence data from North Carolina were collected by the North Carolina Central Cancer Registry, Raleigh, North Carolina. Cancer incidence data from Pennsylvania were supplied by the Division of Health Statistics and Research, Pennsylvania Department of Health, Harrisburg, Pennsylvania. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions. Cancer incidence data from Arizona were collected by the Arizona Cancer Registry, Division of Public Health Services, Arizona Department of Health Services, Phoenix, Arizona. Cancer incidence data from Texas were collected by the Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services, Austin, Texas. Cancer incidence data from Nevada were collected by the Nevada Central Cancer Registry, Division of Public and Behavioral Health, State of Nevada Department of Health and Human Services, Carson City, Nevada.

We are indebted to the participants in the NIH-AARP Diet and Health Study for their outstanding cooperation. We also thank Sigurd Hermansen and Kerry Grace Morrissey from Westat for study outcomes ascertainment and management and Leslie Carroll at Information Management Services for data support and analysis.

The PLCO Study is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, and contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. Cancer incidence data have been provided by the Alabama Statewide Cancer Registry, Arizona Cancer Registry, Colorado Central Cancer Registry, District of Columbia Cancer Registry, Georgia Cancer Registry, Hawaii Cancer Registry, Cancer Data Registry of Idaho, Maryland Cancer Registry, Michigan Cancer Surveillance Program, Minnesota Cancer Surveillance System, Missouri Cancer Registry, Nevada Central Cancer Registry, Ohio Cancer Incidence Surveillance System, Pennsylvania Cancer Registry, Texas Cancer Registry, Utah Cancer Registry, Virginia Cancer Registry, and Wisconsin Cancer Reporting System. All are supported in part by funds from the Center for Disease Control and Prevention, National Program for Central Registries, local states, or by the National Cancer Institute, Surveillance, Epidemiology, and End Results program. The results reported here and the conclusions derived are the sole responsibility of the authors.

We are indebted to the participants of the PLCO Study for their participation.

CONFLICT OF INTEREST

There were no conflicts of interest.

AUTHOR CONTRIBUTIONS

Ashley M. Geczik: Study design, statistical analysis, data interpretation, writing, and critical review of the article. Michael B. Cook, Scott P. Kelly, and Louise A. Brinton: Study conception, study design, data interpretation, and critical review of the article. Cindy K. Zhou and Ruth M. Pfeiffer: Study design, statistical analysis consultation, data interpretation, and critical review of the article. Wen-Yi Huang and Linda M. Liao: Study management, data interpretation, and critical review of the article.

DATA AVAILABILITY STATEMENT

NIH-AARP: Data are available upon submitting a proposal to be approved by the NIH-AARP Steering Committee at https://www.nihaarpstars.com/.

PLCO: Requests for access to the data underlying this article should be submitted through the PLCO Cancer Data Access System at https://cdas.cancer.gov/learn/plco/instr uctions/?type=data.

ORCID

Ashley M. Geczik D https://orcid.org/0000-0002-4635-8783

REFERENCES

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer J Clin. 2020;70(1):7-30.
- Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*. 2018;50(7):928-936.
- Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. *Cold Spring Harb Perspect Med*. 2018;8(12):a030361.
- Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. *Int J Cancer*. 2007;121(7):1571-1578.
- Walsh TJ, Schembri M, Turek PJ, et al. Increased risk of high-grade prostate cancer among infertile men. *Cancer*. 2010;116(9):2140-2147.
- Mao Y, Xu X, Zheng X, Xie L. Reduced risk of prostate cancer in childless men as compared to fathers: a systematic review and meta-analysis. *Sci Rep.* 2016;6:19210.
- Perez-Cornago A, Key TJ, Allen NE, et al. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. *Br J Cancer*. 2017;117(10):1562-1571.
- Eisenberg ML, Park Y, Brinton LA, Hollenbeck AR, Schatzkin A. Fatherhood and incident prostate cancer in a prospective US cohort. *Int J Epidemiol*. 2011;40(2):480-487.
- Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. *Control Clin Trials*. 2000;21(6 Suppl):273s-309s.
- Al-Jebari Y, Elenkov A, Wirestrand E, Schutz I, Giwercman A, Lundberg GY. Risk of prostate cancer for men fathering through

assisted reproduction: nationwide population based register study. BMJ (Clin Res Ed). 2019;366:15214.

- Gupta N, Sudhakar DVS, Gangwar PK, et al. Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility. *Sci Rep.* 2017;7(1):11225.
- Motrich RD, Salazar FC, Breser ML, et al. Implications of prostate inflammation on male fertility. *Andrologia*. 2018;50(11):e13093.
- 13. Patel R, Khalifa AO, Isali I, Shukla S. Prostate cancer susceptibility and growth linked to Y chromosome genes. *Front Biosci (Elite Ed)*. 2018;10:423-436.
- Nagirnaja L, Aston KI, Conrad DF. Genetic intersection of male infertility and cancer. *Fertil Steril*. 2018;109(1):20-26.
- 15. Mima M, Greenwald D, Ohlander S. Environmental toxins and male fertility. *Curr Urol Rep.* 2018;19(7):50.
- 16. Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. *Nat Rev Urol.* 2016;13(7):379-386.
- Lo EM, Hotaling JM, Pastuszak AW. Urologic conditions associated with malignancy. *Urol Oncol.* 2020;38(1):23-30.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Geczik AM, Kelly SP, Pfeiffer RM, et al. Fatherhood status in relation to prostate cancer risks in two large U.S.-based prospective cohort studies. *Cancer Med.* 2021;10: 405–415. https://doi.org/10.1002/cam4.3606